查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1573078

水痘天皰瘡市場：按藥物類別、給藥途徑、最終用戶、年齡層、治療類型、嚴重程度、診斷測試 - 2025-2030 年全球預測

Bullous pemphigoid Market by Drug Class (Biologics, Corticosteroids, Immunosuppressants), Route Of Administration (Intravenous, Oral, Topical), End-User, Age Group, Treatment Type, Severity, Diagnosis Test - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，水痘天皰瘡市場價值為3.4528億美元，預計到2024年將達到3.5838億美元，複合年成長率為5.60%，到2030年將達到5.0568億美元。

水痘天皰瘡是一種罕見的自體免疫皮膚病，其特徵是充滿液體的大水痘，主要影響老年人。治療這種疾病的療法和產品市場包括皮質類固醇、免疫抑制劑和新型生物製藥等處方藥，以及用於症狀管理的非處方護膚品。人口老化的加劇以及對更安全、更有效、副作用更少的治療方法的需求支持了開拓這個市場的需求。主要最終用戶包括皮膚科醫生、醫院和專科診所，其中重點關注醫療保健提供者。當前的市場成長是由生物治療方法的進步、自體免疫疾病意識的提高以及醫療保健支出的增加所推動的。標靶治療的發展是目前主要的成長催化劑，為製藥公司考慮個人化醫療方法提供了重要機會。然而，生物製藥的高成本、由於疾病罕見而導致的患者群體有限以及潛在的監管障礙等挑戰可能會抑製成長。解決這些限制需要繼續探索具有成本效益的治療方法，並開發新型藥物輸送系統，以提高患者的依從性和治療結果。生物相似藥和針對患者的治療方案代表了一個創新領域，可以提供經濟效益和客製化治療。此外，製藥公司和研究機構之間的夥伴關係有可能加速新療法的發現並加速臨床試驗過程。希望從這個市場中獲利的公司應該投資於提高其研發能力並建立合作夥伴關係，使他們能夠有效地與監管機構打交道。由於市場的研究主導和高度監管的性質，持續關注新興研究趨勢和以患者為中心的解決方案對於持續的業務成長和擴張至關重要。

主要市場統計
基準年[2023] 3.4528億美元
預測年份 [2024] 3.5838億美元
預測年份 [2030] 50568萬美元
複合年成長率（%） 5.60%

市場動態：快速發展的水痘天皰瘡市場的關鍵市場洞察

供需的動態交互作用正在改變水痘天皰瘡市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 醫療費用的增加和政府的支持政策改善了水痘天皰瘡治療的機會
    • 擴大新興國家的醫療保健基礎設施以促進市場滲透和成長
    • 水痘天皰瘡治療臨床試驗數量增加，提高市場競爭力
  • 市場限制因素
    • 缺乏專門治療水痘類天皰瘡的醫療專業人員影響了市場成長
  • 市場機會
    • 引入先進的診斷工具以改善水痘天皰瘡的早期檢測
    • 水痘天皰瘡藥企與研究機構策略聯盟
  • 市場挑戰
    • 用於水痘天皰瘡市場早期檢測的先進診斷工具的可用性有限

波特的五力：駕馭水痘天皰瘡市場的策略工具

波特的五力框架是了解水痘天皰瘡市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解水痘天皰瘡市場的外部影響

外部宏觀環境因素在塑造水痘天皰瘡市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解水痘類天皰瘡市場的競爭格局

水痘天皰瘡市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣水痘天皰瘡市場供應商的績效評估

FPNV定位矩陣是評估水痘天皰瘡市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了水痘天皰瘡市場的成功之路

對於希望加強其在全球市場的影響力的公司來說，對水痘天皰瘡市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 醫療保健成本增加和政府支持政策增加了獲得水痘天皰瘡治療的機會
      • 新興國家醫療保健基礎設施的擴張推動市場滲透和成長
      • 水痘天皰瘡治療方法臨床試驗數量增加提高市場競爭力
    • 抑制因素
      • 缺乏專門治療水痘類天皰瘡的醫療專業人員影響了市場成長
    • 機會
      • 實施先進的診斷工具以改善水痘天皰瘡的早期發現
      • 藥廠與研究機構策略夥伴關係水痘天皰瘡
    • 任務
      • 大皰性類水痘市場用於早期檢測的先進診斷工具的可用性有限
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 大皰性類水痘市場：依藥物類別

  • 生物製藥
    • Rituximab
  • 皮質類固醇
    • 全身性皮質類固醇
    • 局部皮質類固醇
  • 免疫抑制劑
    • Azathioprine
    • 胺基甲基葉酸
    • Mycophenolate Mofetil

第7章 大皰性類水痘市場：依給藥途徑

  • 靜脈
  • 口服
  • 局部的

第 8 章 大皰性類水痘市場：依最終使用者分類

  • 診所
  • 居家護理
  • 醫院
    • 私立醫院
    • 公立醫院

第 9 章 大皰性類水痘市場：依年齡層

  • 成人
  • 老年病
  • 小兒科

第 10 章 大皰性類水痘市場：依治療類型

  • 一線治療
  • 維持治療
  • 二線治療

第11章 大皰性類水痘市場：依嚴重程度

  • 溫和的
  • 適度
  • 嚴重

第12章 大皰性類水痘市場：透過診斷測試

  • 切片檢查
  • 直接螢光
  • 酵素連結免疫吸附試驗
  • 間接螢光

第13章北美與南美洲水痘天皰瘡市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第14章亞太水痘天皰瘡市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第15章歐洲、中東和非洲的水痘天皰瘡市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • 1. AbbVie
  • 2. Alexion Pharmaceuticals
  • 3. Almirall
  • 4. Amgen
  • 5. AstraZeneca
  • 6. Biogen
  • 7. Bristol-Myers Squibb
  • 8. Dermira
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche
  • 11. GlaxoSmithKline
  • 12. Horizon Therapeutics
  • 13. Johnson & Johnson
  • 14. Merck & Co.
  • 15. Novartis
  • 16. Pfizer
  • 17. Regeneron Pharmaceuticals
  • 18. Sanofi
  • 19. Takeda Pharmaceutical Company
  • 20. UCB SA
Product Code: MRR-535C62918796

The Bullous pemphigoid Market was valued at USD 345.28 million in 2023, expected to reach USD 358.38 million in 2024, and is projected to grow at a CAGR of 5.60%, to USD 505.68 million by 2030.

Bullous pemphigoid is a rare autoimmune skin disease characterized by large, fluid-filled blisters, primarily affecting the elderly. The market for therapies and products addressing this condition involves prescription drugs like corticosteroids, immunosuppressants, and novel biologics, as well as over-the-counter skincare products for symptom management. The necessity of developments in this market is underscored by an increasing aging population and the need for safer, more effective treatments with fewer side effects. Key end-users include dermatologists, hospitals, and specialty clinics, highlighting a significant focus on healthcare providers. Current market growth is propelled by advancements in biologic treatments, growing awareness about autoimmune diseases, and increased healthcare spending. The development of targeted therapies, which are currently a primary growth catalyst, provides substantial opportunities for pharmaceutical companies to consider personalized medicine approaches. However, challenges such as the high cost of biologics, limited patient populations due to the disease's rarity, and potential regulatory hurdles can impede growth. Addressing these limitations calls for continued research into cost-effective treatment options and leveraging novel drug delivery systems to enhance patient compliance and outcomes. There is a robust area for innovation in biosimilars and patient-specific treatment protocols, which could offer both economic advantages and customized care. Furthermore, partnerships between pharmaceutical companies and research institutions could facilitate the discovery of new therapeutics and expedite clinical testing processes. Businesses seeking to capitalize on this market should invest in growing their R&D capabilities and establishing alliances to navigate regulatory pathways effectively. As the market nature is research-driven and heavily regulated, maintaining a keen focus on emerging research trends and patient-centric solutions is crucial for sustained business growth and expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 345.28 million
Estimated Year [2024] USD 358.38 million
Forecast Year [2030] USD 505.68 million
CAGR (%) 5.60%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Bullous pemphigoid Market

The Bullous pemphigoid Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising healthcare expenditure and supportive government policies enhancing access to bullous pemphigoid treatments
    • Expansion of healthcare infrastructure in emerging economies facilitating market penetration and growth
    • Growing number of clinical trials for bullous pemphigoid treatments increasing market competitiveness
  • Market Restraints
    • Lack of medical professionals specializing in bullous pemphigoid affecting market growth
  • Market Opportunities
    • Implementation of advanced diagnostic tools to improve early detection of bullous pemphigoid
    • Strategic partnerships between pharmaceutical companies and research institutes for bullous pemphigoid
  • Market Challenges
    • Limited availability of advanced diagnostic tools for early detection in bullous pemphigoid market

Porter's Five Forces: A Strategic Tool for Navigating the Bullous pemphigoid Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Bullous pemphigoid Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Bullous pemphigoid Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Bullous pemphigoid Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Bullous pemphigoid Market

A detailed market share analysis in the Bullous pemphigoid Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Bullous pemphigoid Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Bullous pemphigoid Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Bullous pemphigoid Market

A strategic analysis of the Bullous pemphigoid Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Bullous pemphigoid Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Alexion Pharmaceuticals, Almirall, Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Dermira, Eli Lilly and Company, F. Hoffmann-La Roche, GlaxoSmithKline, Horizon Therapeutics, Johnson & Johnson, Merck & Co., Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi, Takeda Pharmaceutical Company, and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Bullous pemphigoid Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Biologics, Corticosteroids, and Immunosuppressants. The Biologics is further studied across Rituximab. The Corticosteroids is further studied across Systemic Corticosteroids and Topical Corticosteroids. The Immunosuppressants is further studied across Azathioprine, Methotrexate, and Mycophenolate Mofetil.
  • Based on Route Of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on End-User, market is studied across Clinics, Home Care, and Hospitals. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Age Group, market is studied across Adults, Geriatric, and Pediatric.
  • Based on Treatment Type, market is studied across First-Line Treatment, Maintenance Treatment, and Second-Line Treatment.
  • Based on Severity, market is studied across Mild, Moderate, and Severe.
  • Based on Diagnosis Test, market is studied across Biopsy, Direct Immunofluorescence, Elisa, and Indirect Immunofluorescence.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising healthcare expenditure and supportive government policies enhancing access to bullous pemphigoid treatments
      • 5.1.1.2. Expansion of healthcare infrastructure in emerging economies facilitating market penetration and growth
      • 5.1.1.3. Growing number of clinical trials for bullous pemphigoid treatments increasing market competitiveness
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of medical professionals specializing in bullous pemphigoid affecting market growth
    • 5.1.3. Opportunities
      • 5.1.3.1. Implementation of advanced diagnostic tools to improve early detection of bullous pemphigoid
      • 5.1.3.2. Strategic partnerships between pharmaceutical companies and research institutes for bullous pemphigoid
    • 5.1.4. Challenges
      • 5.1.4.1. Limited availability of advanced diagnostic tools for early detection in bullous pemphigoid market
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bullous pemphigoid Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. Rituximab
  • 6.3. Corticosteroids
    • 6.3.1. Systemic Corticosteroids
    • 6.3.2. Topical Corticosteroids
  • 6.4. Immunosuppressants
    • 6.4.1. Azathioprine
    • 6.4.2. Methotrexate
    • 6.4.3. Mycophenolate Mofetil

7. Bullous pemphigoid Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Intravenous
  • 7.3. Oral
  • 7.4. Topical

8. Bullous pemphigoid Market, by End-User

  • 8.1. Introduction
  • 8.2. Clinics
  • 8.3. Home Care
  • 8.4. Hospitals
    • 8.4.1. Private Hospitals
    • 8.4.2. Public Hospitals

9. Bullous pemphigoid Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Geriatric
  • 9.4. Pediatric

10. Bullous pemphigoid Market, by Treatment Type

  • 10.1. Introduction
  • 10.2. First-Line Treatment
  • 10.3. Maintenance Treatment
  • 10.4. Second-Line Treatment

11. Bullous pemphigoid Market, by Severity

  • 11.1. Introduction
  • 11.2. Mild
  • 11.3. Moderate
  • 11.4. Severe

12. Bullous pemphigoid Market, by Diagnosis Test

  • 12.1. Introduction
  • 12.2. Biopsy
  • 12.3. Direct Immunofluorescence
  • 12.4. Elisa
  • 12.5. Indirect Immunofluorescence

13. Americas Bullous pemphigoid Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Bullous pemphigoid Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Bullous pemphigoid Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
  • 16.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Alexion Pharmaceuticals
  • 3. Almirall
  • 4. Amgen
  • 5. AstraZeneca
  • 6. Biogen
  • 7. Bristol-Myers Squibb
  • 8. Dermira
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche
  • 11. GlaxoSmithKline
  • 12. Horizon Therapeutics
  • 13. Johnson & Johnson
  • 14. Merck & Co.
  • 15. Novartis
  • 16. Pfizer
  • 17. Regeneron Pharmaceuticals
  • 18. Sanofi
  • 19. Takeda Pharmaceutical Company
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. BULLOUS PEMPHIGOID MARKET RESEARCH PROCESS
  • FIGURE 2. BULLOUS PEMPHIGOID MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. BULLOUS PEMPHIGOID MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. BULLOUS PEMPHIGOID MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BULLOUS PEMPHIGOID MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BULLOUS PEMPHIGOID MARKET DYNAMICS
  • TABLE 7. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY RITUXIMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AZATHIOPRINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MYCOPHENOLATE MOFETIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY FIRST-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MAINTENANCE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SECOND-LINE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MILD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY DIRECT IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BULLOUS PEMPHIGOID MARKET SIZE, BY INDIRECT IMMUNOFLUORESCENCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES BULLOUS PEMPHIGOID MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 205. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 216. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 227. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 238. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 249. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BULLOUS PEMPHIGOID MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 272. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 283. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 294. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 295. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 305. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 306. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 316. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 317. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 318. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 319. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 320. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 321. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 322. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 323. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 324. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 327. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 328. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 329. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 330. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 331. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 332. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 333. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 334. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 335. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 337. ISRAEL BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 338. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 339. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 340. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD MILLION)
  • TABLE 341. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY IMMUNOSUPPRESSANTS, 2018-2030 (USD MILLION)
  • TABLE 342. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 343. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 344. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 345. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 346. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY SEVERITY, 2018-2030 (USD MILLION)
  • TABLE 348. ITALY BULLOUS PEMPHIGOID MARKET SIZE, BY DIAGNOSIS TEST, 2018-2030 (USD MILLION)
  • TABLE 349. NETHERLANDS BULLOUS PEMPHIGOID MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 350. NETHERLANDS BULLOUS PEMPHIGOID MARKET SI